Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
about
Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemiaTyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous LeukemiaConditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.Allogeneic transplantation for CML in the TKI era: striking the right balance.Molecular monitoring of chronic myeloid leukemia: present and future.Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.Ponatinib in the therapy of chronic myeloid leukemia.Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.Prognostic discrimination based on the EUTOS long term survival score within the international registry for chronic myeloid leukemia in children and adolescents.Chronic myeloid leukemia: room for improvement?Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.Cancer statistics, 2018.Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.Dasatinib dose management for the treatment of chronic myeloid leukemia.Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib.Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
P2860
Q27027369-207440EE-E685-4BBC-811E-78624459B88DQ33806617-96941899-C4D5-4784-A5B8-E547C2E24BD7Q36450182-CD502328-A64E-4E3E-8C92-E3B466F6C0B6Q36624496-C4AC3F4B-9F45-4435-AA96-AA93A9FF3B62Q37391801-52CBA46E-2753-4C28-93B2-D56F72D8175AQ37427140-46FB909E-9F70-486A-A2BE-293B11BD1ABEQ37696776-8791CA46-5B5B-47CD-AA5E-5AC0A6786BA2Q38598820-B567369B-8D41-4C28-B5E9-EA7BB49BD5A7Q38620872-443EDCDE-8340-480D-A2EE-5E10860A8B68Q38634736-05F49C90-D637-41DA-8307-B30099D0B99CQ38828713-36DAB6AF-3816-431F-A847-1B02610DBCD9Q38934423-F0D6ACA1-6A73-4278-827D-E07E6C72418BQ38945162-06065B32-3AF7-4D07-8B9C-4047429D0EFBQ39209783-7871EDB9-6A09-47D4-818C-05EF3E62B837Q39259447-6D444601-77BC-40B9-BC45-A7E4135AC968Q40071286-91A4257A-9E71-42FF-9554-E0A22C8EDD5AQ42348447-3353642D-E157-4A65-B651-490828E1A24EQ42391592-43A1D30A-8B0B-43A9-ACBF-45C1BEF35DF2Q46976339-22EABEED-5086-43F3-92E0-E15E3C26621DQ47191906-97596662-8C9E-439D-AA13-4472E93299DEQ47269765-D971A9ED-E4B5-4B02-A306-C71DBD3237BDQ47551814-D2EB5838-125B-4740-AE10-1074DB8E33D7Q48165102-2178A30B-04A1-4BEC-BCE2-D9BB4E974622Q49952452-51C9494D-72A0-4D1E-9D0E-F1D890BA8789Q52816089-EC9494EB-1F06-471B-AFEA-0EDE0DB85053Q54839818-89EDAF6A-F37C-4D97-9914-B0F5ACC1519BQ54977220-A2348420-7835-47E6-8169-58150F3872FBQ58767811-D032BF52-F60E-4232-9B86-46C236E73B0C
P2860
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Relative survival in patients ...... ix prospective clinical trials
@ast
Relative survival in patients ...... ix prospective clinical trials
@en
type
label
Relative survival in patients ...... ix prospective clinical trials
@ast
Relative survival in patients ...... ix prospective clinical trials
@en
prefLabel
Relative survival in patients ...... ix prospective clinical trials
@ast
Relative survival in patients ...... ix prospective clinical trials
@en
P2093
P2860
P50
P1476
Relative survival in patients ...... ix prospective clinical trials
@en
P2093
Naval Daver
Naveen Pemmaraju
Sara S Strom
P2860
P304
P356
10.1016/S2352-3026(15)00048-4
P50
P577
2015-04-20T00:00:00Z